文献速递浆细胞疾病造血干细胞移植与细胞治疗

大剂量美法仑联合自体干细胞移植在多发性骨髓瘤中的作用:是时候转变范式了吗?

The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift?
PubMed 文献 · Br J Haematol · 2020-06-05

本综述讨论诱导治疗进展对HDM-ASCT价值的影响、MRD检测的演变作用及HDM-ASCT的短期和长期风险。作者认为,鉴于前瞻性数据有限,对于接受高效方案并达到深度缓解的符合条件的新诊断患者,HDM-ASCT不应被视为强制,而应保留备用,避免早期暴露于其固有的临床和基因组毒性。

要点

  • 高效诱导方案联合维持治疗已带来变革性临床获益。
  • 含单克隆抗体的四药方案在未强化治疗下报告了前所未有的完全缓解和MRD阴性率。
  • 作者建议HDM-ASCT对高效方案后深度缓解者不作强制,保留备用。

核心结论

  • 作者认为,鉴于前瞻性数据有限,对于接受高效方案并达到深度缓解的符合条件的新诊断患者,HDM-ASCT不应被视为强制,而应保留备用,避免早期暴露于其固有的临床和基因组毒性。

研究设计与样本

  • 本文为综述,讨论诱导治疗进展、其对HDM-ASCT的影响、MRD检测的演变作用及HDM-ASCT的短期和长期风险。

主要发现

  • 含单克隆抗体的四药方案在未强化治疗下报告了前所未有的完全缓解率和MRD阴性率。
  • HDM-ASCT与降低生活质量的急性毒性相关。
  • HDM-ASCT与可能限制部分患者预期寿命的长期毒性相关。

临床怎么用

  • 作者建议,对于接受高效方案并达到深度缓解的符合条件的新诊断患者,HDM-ASCT不应被视为强制,而应保留备用。

局限性

  • 作者指出前瞻性数据仍然有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recent advances in multiple myeloma include numerous approvals of novel therapies with unprecedented efficacy, a rapid and sustained tempo of new drug development, and further refinements to prognostication to include minimal residual disease (MRD) testing and improved risk stratification. The upfront use of immunomodulatory drug and proteasome inhibitor combinations followed by maintenance has resulted in transformative clinical benefit. Four-drug regimens incorporating monoclonal antibodies are reporting unprecedented rates of complete response and MRD negativity in the absence of intensification. In the context of these advances, the added value of high-dose melphalan with autologous stem-cell transplant (HDM-ASCT) is a key question. From a safety standpoint, HDM-ASCT is associated with both acute toxicities that reduce quality of life and long-term toxicities that may limit life expectancy for some patients. The present review discusses the recent advances in induction therapy, the impact of these advances on HDM-ASCT, the evolving role of MRD testing and the short- and long-term risks of HDM-ASCT. Recognising that prospective data remains limited, we suggest that HDM-ASCT not be considered mandatory for eligible newly diagnosed patients who are treated with highly efficacious regimens and achieve deep responses, but rather be held in reserve without early exposure to the clinical and genomic toxicity inherent to this approach.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kazandjian D, Mo CC, Landgren O, et al. The role of high-dose melphalan with autologous stem-cell transplant in multiple myeloma: is it time for a paradigm shift? Br J Haematol. 2020. PMID: 32501533. doi:10.1111/bjh.16764

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。